Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1 H -indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate

Stefano Crosignani (1) , Patrick Bingham (2) , Pauline Bottemanne (1) , Hélène Cannelle (1) , Sandra Cauwenberghs (1) , Marie Cordonnier (1) , Deepak Dalvie (2) , Frederik Deroose (3) , Jun Li Feng (2) , Bruno Gomes (1) , Samantha Greasley (2) , Stephen Kaiser (2) , Manfred Kraus (2) , Michel Negrerie (1, 4) , Karen Maegley (2) , Nichol Miller (2) , Brion Murray (2) , Manfred Schneider (1) , James Soloweij (2) , Albert Stewart (2) , Joseph Tumang (2) , Vince Torti (2) , Benoit van den Eynde (5) , Martin Wythes (2)

1 iTeos - iTeos Therapeutics
2 Pfizer
3 Asclepia Outsourcing Solutions
4 LOB - Laboratoire d'Optique et Biosciences
5 UCL - Université Catholique de Louvain = Catholic University of Louvain

Domaines: Biochimie, Biologie Moléculaire

Stefano Crosignani, Patrick Bingham, Pauline Bottemanne, Hélène Cannelle, Sandra Cauwenberghs, et al.. Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1 H -indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate. Journal of Medicinal Chemistry, 2017, 60 (23), pp.9617 - 9629. ⟨10.1021/acs.jmedchem.7b00974⟩. ⟨hal-01760561⟩